Withdraw of SGLT2 inhibitor should not be recommended before PCI, to avoid inappropriate discouragement of the use of this novel class of agents that otherwise appear to afford significant long-term cardiovascular and renal protection in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.